These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

82 related articles for article (PubMed ID: 8192933)

  • 1. [Comparative study on cytotoxicity of lymphocytes from different tissues in laryngeal cancer].
    An W
    Zhonghua Er Bi Yan Hou Ke Za Zhi; 1993; 28(5):292-4, 314-5. PubMed ID: 8192933
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cytotoxicity against autologous, allogeneic, and xenogeneic tumor targets by human recombinant interleukin-2-activated lymphocytes from healthy dogs and dogs with lung tumors.
    Mitchell DH; Withrow SJ; Johnston MR; Kruse CA
    Am J Vet Res; 1991 Jul; 52(7):1132-6. PubMed ID: 1892269
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A study of the cytotoxicity of malignant pleural effusion lymphocytes and LAK cells against autologous tumor cells.
    Guo YS; Xing ZL
    Chin Med J (Engl); 1994 Dec; 107(12):903-5. PubMed ID: 7882727
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Adoptive immunotherapy in patients with multiple hepatic cancers using lymphokine activated killer cells (LAK) and interleukin-2].
    Kanai T; Monden M; Takeda T; Gotoh M; Sakon M; Umeshita K; Hasuike Y; Sakita I; Nakano H; Yoshida T
    Gan To Kagaku Ryoho; 1993 Aug; 20(11):1457-60. PubMed ID: 8396896
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [The characteristic of lymphokine-activated killer cells induced from tumor draining lymph-node cell].
    Meng YG; Fu CY; Wang YZ
    Zhonghua Fu Chan Ke Za Zhi; 1994 Sep; 29(9):535-7, 574. PubMed ID: 7835130
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [An experimental study of the antitumor activity of tumor-infiltrating lymphocytes (TIL) in human tongue carcinoma in vitro].
    Guo W
    Zhonghua Kou Qiang Yi Xue Za Zhi; 1992 Sep; 27(5):259-61, 318. PubMed ID: 1306434
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Treatment with autologous tumor-infiltrating lymphocytes and recombinant interleukin-2 in patients with lung carcinoma].
    Li D; Zhang X; Song Y
    Zhonghua Zhong Liu Za Zhi; 1995 Mar; 17(2):152-5. PubMed ID: 7656811
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Studies on adoptive immunotherapy using recombinant interleukin 2].
    Sugiyama Y; Takao H; Saji S; Sakata K
    Gan To Kagaku Ryoho; 1986 Apr; 13(4 Pt 2):1307-13. PubMed ID: 3488028
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cytotoxic activity of various LAK cells against autologous lung cancer, K-562 and Daudi cells.
    Kimura H; Yamaguchi Y
    Jpn J Clin Oncol; 1989 Sep; 19(3):222-8. PubMed ID: 2810822
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Induction of lymphokine-activated killer activities in peripheral blood lymphocytes and regional lymph node lymphocytes against PC-9 cultured adenocarcinoma and autologous pulmonary adenocarcinoma cells.
    Morikawa Y; Watanabe S; Kodama T
    Jpn J Clin Oncol; 1987 Jun; 17(2):129-39. PubMed ID: 3497285
    [TBL] [Abstract][Full Text] [Related]  

  • 11. IL-4 inhibits IL-2 induction of LAK cytotoxicity in lymphocytes from a variety of lymphoid tissues.
    Colquhoun SD; Economou JS; Shau H; Golub SH
    J Surg Res; 1993 Nov; 55(5):486-92. PubMed ID: 8231167
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunosensitization of prostate carcinoma cell lines for lymphocytes (CTL, TIL, LAK)-mediated apoptosis via the Fas-Fas-ligand pathway of cytotoxicity.
    Frost P; Ng CP; Belldegrun A; Bonavida B
    Cell Immunol; 1997 Aug; 180(1):70-83. PubMed ID: 9316641
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Induction by OK-432 of lymphokine activated killer precursor cells in hepatocellular carcinoma.
    Aramaki M; Kim YI; Shimoda K; Nakashima K; Okada K; Kobayashi M
    Hepatogastroenterology; 1994 Aug; 41(4):363-6. PubMed ID: 7959572
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [The cytotoxicity of malignant pleural effusion lymphocytes and LAK cells against autologous tumor cells].
    Guo Y; Xing Z
    Zhonghua Jie He He Hu Xi Za Zhi; 1995 Apr; 18(2):80-2, 127. PubMed ID: 7553955
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lymphokine-activated killer cells can kill target cells not only by early killing but also by late killing, and the late killing level against autotumor cell line.
    Komatsu F; Ishiguro K
    Oncol Res; 2003; 13(4):235-41. PubMed ID: 12659424
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Comparison of antitumor activity of tumor draining lymph node lymphocytes and peripheral blood lymphocytes in human oral cancer].
    Guo W; Qiu WL; He RG
    Zhonghua Kou Qiang Yi Xue Za Zhi; 1994 Nov; 29(6):336-8, 384. PubMed ID: 7743875
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of basic procedures for adoptive immunotherapy for gastric cancer.
    Fujimoto T; Omote K; Mai M; Natsuume-Sakai S
    Biotherapy; 1992; 5(2):153-63. PubMed ID: 1524956
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Adoptive immunotherapy of cancer patients with lymphokine-activated killer cells].
    Taguchi T; Domoto K
    Gan To Kagaku Ryoho; 1987 Mar; 14(3 Pt 2):914-21. PubMed ID: 3494428
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical and biological effects of intraperitoneal injections of recombinant interferon-gamma and recombinant interleukin 2 with or without tumor-infiltrating lymphocytes in patients with ovarian or peritoneal carcinoma.
    Freedman RS; Kudelka AP; Kavanagh JJ; Verschraegen C; Edwards CL; Nash M; Levy L; Atkinson EN; Zhang HZ; Melichar B; Patenia R; Templin S; Scott W; Platsoucas CD
    Clin Cancer Res; 2000 Jun; 6(6):2268-78. PubMed ID: 10873077
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [The effect of MPS on LAK cell growth and its cytotoxic activity against laryngeal cancer (HEP-2)].
    Wang J; Zhu X; Chen J
    Zhonghua Er Bi Yan Hou Ke Za Zhi; 1996; 31(5):283-6. PubMed ID: 9642362
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.